Table of Contents Author Guidelines Submit a Manuscript

Cognitive Changes and Promotion in Parkinson’s Disease

Call for Papers

Cognitive impairment in Parkinson’s disease (PD) is one of the common complications of PD, with personal differences in clinical symptoms and disease progression. Current studies are not only concerned with Parkinson’s disease dementia (PDD), but also concerned with Parkinson’s disease mild cognitive impairment (PD-MCI), which is considered a clinical precursor to PDD. Recent advances have been made in the clinical features, definitions, biomarkers, and risk factors of PD-MCI and PDD. But there is still lack of effective clinical treatment in PD-MCI and PDD. In US Food and Drug Administration, rivastigmine is the only one approved for the treatment of PDD. In recent years, treatment of PDD and PD-MCI drugs are mainly concentrated in AD drugs, such as cholinesterase inhibitors and NMDA receptor antagonist (memantine). Besides, nondrug therapy, including mental and motor training and nerve stimulation, is also under study.

Implicit cognitive changes of Basal ganglia; memory can be divided into explicit memory and implicit memory. Explicit memory consists of episodic memory and semantic memory. The hippocampus and cortex nearby are major regions associated with explicit memory. Implicit memory is recollected consciously and unconsciously and can be inferred on the basis of improved achievements of tasks, with the involvement of the Basal ganglia. There are subsystems of memory functions in the brain and each subsystem of memory, which is composed of networks of neurons with relatively independent functions. Different memory impairments follow the damage of the different regions of the brain. Cognitive change in PD is always concerned specifically.

The current special issue is mainly to collect information on the subject of PD cognitive disorder about human and other species. The purpose of this special issue is to present high-quality reviews and research articles on cognitive changes and promotion in PD, as well as future prospects and challenges.

Potential topics include but are not limited to the following:

  • Diagnostic criteria of dementia in Parkinson’s disease
  • Implicit cognitive changes in Parkinson’s disease
  • Emerging mechanisms of cognitive changes in Parkinson’s disease
  • Neuroimaging of brain changes of cognitive impairment in Parkinson’s disease
  • Metabolism factors associated with dementia in Parkinson’s disease
  • Study on cognitive impairment of Parkinson’s disease by animal model
  • Biomarkers of cognitive impairment in patients with Parkinson’s disease
  • Treatment of cognitive impairment in patients with Parkinson’s disease, such as drug, cognitive rehabilitation, and nerve stimulation
  • Cognitive changes following deep brain stimulation in Parkinson’s disease
  • Subtypes of mild cognitive impairment in Parkinson’s disease and factors that predict dementia

Authors can submit their manuscripts through the Manuscript Tracking System at

Submission DeadlineFriday, 23 March 2018
Publication DateAugust 2018

Papers are published upon acceptance, regardless of the Special Issue publication date.

Lead Guest Editor

Guest Editors